{"ticker": {"uuid": "a67e01f6-440f-4bd9-8a2a-556711aeccf9", "symbol": "TRDA", "name": "Entrada Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10", "summary": "Roth MKM has reiterated its Buy rating for Entrada Therapeutics (TRDA.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/70998616/roth-mkm-maintains-entrada-therapeutics-trdaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-15T13:11:06", "published_display": "15 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why (TRDA) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models to provide tactical trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but strong mid and long-term support signals, offering specific entry", "url": "https://news.stocktradersdaily.com/news_release/1/Why_TRDA_Price_Action_Is_Critical_for_Tactical_Trading_071026094802_1783691282.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T10:09:42", "published_display": "10 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of investors. This investigation follows a significant stock price drop of 57.27% on May 7, 2026, after the company announced \"positive\" Phase 1/2 clin", "url": "https://www.natlawreview.com/press-releases/entrada-therapeutics-inc-trda-investigation-bronstein-gewirtz-grossman-llc-2", "source_name": "The National Law Review", "published_at": "2026-07-03T21:10:57", "published_display": "03 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (TRDA)", "summary": "This article analyzes Entrda Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, with speci", "url": "https://news.stocktradersdaily.com/news_release/10/Understanding_Momentum_Shifts_in_TRDA_062926084002_1782736802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T08:12:15", "published_display": "29 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Entrada Therapeutics, Inc. \u2013 NASDAQ:TRDA", "summary": "This article displays the \"Price to book forward\" metric for Entrada Therapeutics, Inc. (NASDAQ: TRDA). It appears to be a financial data point presented within the TradingView platform, with no additional textual analysis or details provided. The content is minimalist, focusing ", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:39:43", "published_display": "28 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Entrada Therapeutics, Inc. \u2013 NASDAQ:TRDA", "summary": "This article provides a brief financial overview for Entrada Therapeutics, Inc. (NASDAQ: TRDA), focusing on its forward price-to-earnings ratio. The content primarily lists navigation and platform features of TradingView, where this financial data is presumably presented, rather ", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:10:17", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Entrada Therapeutics, Inc. \u2013 NASDAQ:TRDA", "summary": "This page provides financial information for Entrada Therapeutics, Inc. (NASDAQ: TRDA) on TradingView, specifically focusing on its price-to-sales forward ratio. It also lists various features and services offered by TradingView, including market data, analytical tools, community", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:50", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA)", "summary": "This article provides an overview of Entrada Therapeutics, Inc. (NASDAQ: TRDA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and past financial result", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:39:39", "published_display": "26 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRDA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Entrada Therapeutics, Inc. (TRDA) stock, including current analyst price targets, ratings, and financial data. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA, along with frequently asked questi", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-23T21:40:42", "published_display": "23 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "The article provides a financial overview of Entrada Therapeutics Inc (TRDA), detailing its revenue breakdown, profitability margins, and a competitive comparison. TRDA boasts a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in ", "url": "https://intellectia.ai/en/stock/TRDA/financials", "source_name": "Intellectia AI", "published_at": "2026-06-21T03:39:12", "published_display": "21 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Entrada Therapeutics Inc (TRDA), highlighting its current valuation score of 6.99 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.77, which is significantly below its recent high. The artic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T13:40:09", "published_display": "18 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Entrada Therapeutics Inc.'s (TRDA) revenue breakdown. It indicates that relevant data for business segments and profit contribution have not yet been disclosed by the company. However, it does provide a revenue figure for the United State", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:14", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (TRDA) Movement", "summary": "This article analyzes Entrada Therapeutics Inc. (", "url": "https://news.stocktradersdaily.com/news_release/11/Avoiding_Lag:_Real-Time_Signals_in_TRDA_Movement_061826072802_1781782082.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-18T07:28:00", "published_display": "18 Jun 2026 07:28", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50, ranking 107th in its industry, with an average analyst price target of $16.50. Analysts predominantly rate TRDA as a \"Buy,\" forecasting an expected revenue of 411.43K for the next quarter and an EPS of -$1.05", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:16", "published_display": "17 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Entrada Therapeutics Inc (TRDA) currently holds a financial score of 6.01, ranking 301st out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company's latest quarterly revenue decreased by 95.74% year-o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T01:09:16", "published_display": "17 Jun 2026 01:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Stockholders Approve Directors and Equity Plans", "summary": "Entrada Therapeutics Inc. stockholders approved key measures at their annual meeting, including the election of two Class II directors, Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D., and the ratification of Ernst & Young LLP as their independent auditor. Shareholders also appro", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TRDA/pressreleases/2430366/entrada-therapeutics-stockholders-approve-directors-and-equity-plans/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T14:39:12", "published_display": "14 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)", "summary": "Oppenheimer has reiterated a Buy rating on Entrada Therapeutics Inc (TRDA) with a price target of $23.00, following an earlier report by Roth MKM which also maintained a Buy rating and a $10.00 price target. The company recently reported a quarterly revenue of $875 thousand and a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TRDA/pressreleases/2303983/oppenheimer-remains-a-buy-on-entrada-therapeutics-inc-trda/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T11:40:19", "published_display": "14 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity", "summary": "Entrada Therapeutics director and 10% owner Kush Parmar was granted 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options will vest on the earlier of the one-year anniversary of June 10, 2026, or the company\u2019s next annual meeting", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-634b6498918f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:49:55", "published_display": "12 Jun 2026 21:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97", "summary": "Entrada Therapeutics (TRDA) director Gina Chapman was granted 19,000 stock options at an exercise price of $5.97 per share. These options will vest on the earlier of one year from June 10, 2026, or the company's next annual meeting, and are set to expire on June 10, 2036. The tra", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-f46b6cda1311.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:39:55", "published_display": "12 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading", "summary": "Entrada Therapeutics director Radhakrishnan Maha was granted 19,000 stock options, allowing him to purchase common stock at an exercise price of $5.97 per share. These options, granted at no cost, will vest on the earlier of June 10, 2027, or the company's next annual meeting, an", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-3ec39f760b08.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:55", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options", "summary": "Entrada Therapeutics director Peter S. Kim received a grant of 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027, or the company's next annual meeting of stockholders. The transaction was ", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-f48bbe69c5f5.html", "source_name": "Stock Titan", "published_at": "2026-06-12T04:10:55", "published_display": "12 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)", "summary": "This article highlights contrasting analyst sentiments for Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) within the healthcare sector. Entrada Therapeutics receives a Strong Buy consensus with significant upside potential, based on a Buy rating from Guggenheim and Roth MKM. In", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE-N/pressreleases/2374960/analysts-have-conflicting-sentiments-on-these-healthcare-companies-entrada-therapeutics-inc-trda-and-pfizer-pfe/", "source_name": "The Globe and Mail", "published_at": "2026-06-09T15:40:40", "published_display": "09 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in TRDA Response", "summary": "This article provides an in-depth analysis of Entrada Therapeutics Inc. (NASDAQ: TRDA) as of June 7, 2026, highlighting weak near-term sentiment but strong mid and long-term signals. It presents AI-generated trading strategies including position, momentum, and risk hedging, along", "url": "https://news.stocktradersdaily.com/news_release/14/Discipline_and_Rules-Based_Execution_in_TRDA_Response_060726055802_1780826282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-07T05:40:09", "published_display": "07 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (NasdaqGM:TRDA) Stock Forecast & Analyst Predictions", "summary": "Entrada Therapeutics (TRDA) is expected to see its earnings decline by 1.6% per annum, while revenue is projected to grow by 44% yearly. Analysts forecast a net loss per share of US$4.09 next year, leading to a recent consensus price target reduction to US$18.75. The company is a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trda/entrada-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-06-05T21:39:48", "published_display": "05 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (TRDA) on behalf of investors. This investigation follows a significant stock price drop after Entrada announced Phase 1/2 clinical study results for a Duchenne treatment, which, d", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-entrada-therapeutics-inc---trda-302789795.html", "source_name": "PR Newswire", "published_at": "2026-06-04T13:39:21", "published_display": "04 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics\u2019 ELEVATE-45-201 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/independent-safety-data-monitoring-committee-110000031.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T11:00:00+00:00", "published_display": "02 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada gets clearance to escalate dose in DMD trial", "summary": "Entrada Therapeutics Inc. (NASDAQ:TRDA) has received clearance from an independent Data Monitoring Committee to escalate the dose in Cohort 2 of its ELEVATE-45-201 study for Duchenne muscular dystrophy (DMD) to 10 mg/kg, up from 5 mg/kg. The decision follows a review of safety an", "url": "https://www.investing.com/news/company-news/entrada-gets-clearance-to-escalate-dose-in-dmd-trial-93CH-4721493", "source_name": "Investing.com", "published_at": "2026-06-02T11:39:15", "published_display": "02 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial", "summary": "Entrada Therapeutics has announced that an independent Data Monitoring Committee has approved an increase in the dose to 10 mg/kg for Cohort 2 in its Phase 1/2 trial for Duchenne muscular dystrophy. This decision follows positive safety and pharmacokinetic reviews of subjects tre", "url": "https://pluang.com/en/news-feed/komite-pengawas-keamanan-rekomendasikan-dosis-tinggi-entrada-therapeutics", "source_name": "Pluang", "published_at": "2026-06-02T11:39:15", "published_display": "02 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare disease trial tests DMD treatment with once-every-six-week dosing", "summary": "Entrada Therapeutics announced that an independent Data Monitoring Committee recommended escalating the dose of ENTR-601-45 to 10 mg/kg for Cohort 2 in its Phase 1/2 ELEVATE-45-201 study for Duchenne muscular dystrophy. All eight participants from Cohort 1, who received 5 mg/kg, ", "url": "https://www.stocktitan.net/news/TRDA/independent-safety-data-monitoring-committee-recommends-initiation-jcyp2i8c61bn.html", "source_name": "Stock Titan", "published_at": "2026-06-02T10:39:15", "published_display": "02 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entrada-therapeutics-announces-inducement-grants-203000634.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:30:00+00:00", "published_display": "01 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPd04wMVAwaUM4QVp6cl95THBzaGxMb01wQzd0ZzNjNE4tMVFzZjVlZDVlN3VuVml6bmNTQnRCdmxfNzhTRzRzVFFvVVoybFlsMldpY0NmSGxuUXlYZ016WGdqdEhOcG1FVGVrMTNKbi02QUtsMG1yT1lfMUNqejUwbGZjbjY0cHZkM3VSeFF6VHdpamJ6dVVRSlRtMFRscm1DVEdpYUw5bnNHUEx6dmJ3SVMzcGlBQndrQnFuSzhEUXU5Vld6M2FoLURrYTVGY0JzNFZrX210Q3MzSV9vN2NJWFlWTjFWZnlocUFKYjdfLXFONHh5UTJn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile", "summary": "", "url": "https://finance.yahoo.com/m/14e3e8c6-ac63-3515-bca1-0399074b5972/entrada-therapeutics-dmd.html", "source_name": "MarketBeat", "published_at": "2026-05-09T06:07:54+00:00", "published_display": "09 May 2026 06:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Downgrades Entrada Therapeutics to Neutral From Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-downgrades-entrada-therapeutics-122234651.html", "source_name": "MT Newswires", "published_at": "2026-05-08T12:22:34+00:00", "published_display": "08 May 2026 12:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada\u2019s stock drops as DMD drug\u2019s efficacy falls short", "summary": "", "url": "https://finance.yahoo.com/m/39e8932f-639c-3a69-8d26-ecf8a3e1e778/entrada%E2%80%99s-stock-drops-as-dmd.html", "source_name": "Clinical Trials Arena", "published_at": "2026-05-08T10:39:36+00:00", "published_display": "08 May 2026 10:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Shares Decline After Duchenne Muscular Dystrophy Drug Reportedly Misses Analyst Expectations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entrada-therapeutics-shares-decline-duchenne-184304757.html", "source_name": "MT Newswires", "published_at": "2026-05-07T18:43:04+00:00", "published_display": "07 May 2026 18:43", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada shares dive as Duchenne results disappoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNc3JWS3JydDgwMFpnUHR0TC13Q3RSVkd4YmJjYXFPdm1YT3RRdlkwMzlENkE0bHROV3piX01qaFl4SHhkOUV2TEswU1NaUlZHT1hLRDJVaExVdVJndF9qc0NxbDNXdjN4dDhudVpPcFlPSjJudGRSV0daX0g1Uk15a1BIR21TazBCdUFNTW1tTFpTRzBZMUlGcA?oc=5", "source_name": "BioPharma Dive", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQY2J6Z1F3UWMzS3dBVTQzOHpYcmtTMjJIZF9XTHlQQUtJeXVUajNVQmhVbnBPNnJOSUpsR0ZPMEhQVUFjTnJnUG5zT0dsTE5jQ1JrVFhWcF9GZVdjUHpPMnBORG5wMFZwRmFXbFQ5eHpBajRHUkE2MVgxNnJFOHdrV0M2N24yMEZ6aUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQOFNodkNpcW5MN1pwRUU5Q1JHNmNmRUc5NWo4d0ZZNzlHRFJPYlF2RzhUQ21aejFDaDB3a005SVg5bDNvbi14bzhSTkpjTWUtOHhZOVduNXpaNzhCVnUxMGRNUGU0Ql9RSmcxMkRDTndsN0tVal9GTk5id211a3FJYXB0SkkwY1oya3luaWR4Ry1ucXFSem9YazkxTnN1MWJReEs3anBaLXR3QQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duchenne trial readout from Entrada arrives Thursday morning", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQNG1YZUROQmpXWWw1ZkdZcjlGOTRreXhmUi1wV1d0c0lNLXh4YkdLZjhRTWJPYUFpV2dqX3FIN0p0M1FQdVpLZjF4TFMxc1Q4WnpaclJJX25PdnRoVmpXWFhVbEl1Z25vbTVVOTE3bDdIVzNoRUZUaHI3bWFqcXFaNl9ySy1lYm1MbG5MN3FkdG53MlhHS3RYMnd5d1hjeFoxbWlOLWppWmdfRUItYUVhQklHMjNXSVBLZFluMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQaUJlNW1wYi1SWWVXZFJaSFBUXzJpRjRMZjZpOGFaV1RKeUdfeFFadHhidkJwV2pHN0VYLW5nbmFGVFFZeUVHTjhfcGZFemVtam9mYUtXRmFTYklnV0ZhYjctdVdFZU1hWlJhQUJIODZlYjBpTEVUaldYay1jVTJRTjBwSVNnc2gzQm1IVjNwSEhwN3ZlTER1YTZ5QXRHWnFZ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxORVJBZ3NfM29DWmQ5ZnR4LVE0enc3TVZ3ZmhuVGJGU2xsSU9JZzd6UGdmeGRHOVd0T2EwdU0xeDREUDZoOUkyZ0NNSU9VX2J3R3VJQlJkTFh5VHNMSV9GU3J1RUNqdU5wRFRadWFEYlpHU21uTXB6WVRLNU5MVkdYeV9CdVZLbkdzYWZQa3ZkTlpfWHZQTVFhWUtPT0JOMUJ2dEZCbmtWUlBwZVUtLXpjR1luckhuYWFiUVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOdTk3aml5UHJkNG9QOTJPMTNoTEkwTnIxc280U0l4ckwxWHpjR3hISUZYNmpIeWxQUW9tZlFERmJwNFQwbGZCYUYzVnZwVlN2emdqYXdUY3NDMW4wV1lYU3FlSWpKNUJfaWp6WEpwZzFFOFJnQzNmeTJpbWdWX0N2M3V4LXNUaElEZ0g0QW0yZlh3dlFMZjh0a1otMURMUkJudXN6a1dNV3M3TjZMcnc?oc=5", "source_name": "Finviz", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNcjhCdWFQZm9lSDVESDVTdFNaYWJkT3NXZzdlVVJGQWdSOS01T1Y1c2V5WXpaSDlCaXRMTVgtek9aN05MQ2k2ZHNlaGZPZUltWVpmdDlBUk9Lb3NBcnBDSGpneFVralpLZzgwUnF6MDBMTE5GVGE0NjNWb3hTN1ZvUUNRR09wSWE5dGhWa01UN0VYNzF2STlVclVFVDdhMllPMXVPaUhvTnBQSUhxZzlxYkMyMjN4R1ktQnFZVkV2QzQ1eE5zRlpUdGRsNE12U0Z4cHZra1VMNWhhVGFi?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxOQWo1U1M2SC1ucEpVU1NsbG9iQVdmZFFHTXMtOVRZNlNJQW05WHFHQlBrMmx5YVhGbFE3ZEdZRnlHenhTb3RDenM0WTZxRXhSYTNyZVRNbjFJbTM4US1DZzI0dlpwaEFMTldHQW8wdWZKcm5tcFhvMmUzUUFkNERjMUVoYjlxVGRRT0RtXzZWSndQcXBrOGlZUjk5M2gzWTg0al82RzhYWTFva3BJZkwwX3hZTWRSMlRNSDhfRGpvTmZ1Ri05dW1lMkdjRFZzVC0ycHRVQWpaN1FmcEtPVlp2S0tqNHhJdDNQNG9TUEZxT2JjSm1feVVj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-09T07:00:00+00:00", "published_display": "09 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1mRlQ4NGktTk5Cc2Q3U0JHVDZMbFR0eWVyMkpjMnJYV3dpSExNZGJ4eTl1V1l2ajRsbDhsU21QZ01PMFR3cDE0OUMxYS1FMDBXUUx3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:39:44+00:00", "published_display": "25 Apr 2025 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics - TRDA - Stock Price Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE1IaGRxVVNYMHZhbXA3TXJSSE5nNmxabkRyYkNoQjl4WkE3cXoteG14TnRxY1lNZHZXUGdCOWlHWWFRSEExdEY4Nm94dUxFeU0?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-11-01T05:34:44+00:00", "published_display": "01 Nov 2021 05:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) Stock Price, News & Analysis $TRDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE43VDJPUWRlc2QzUVYzcGcwX0dkZXdROXluQzFESFk2NXZObjdrSy1ONjQtc3BfZGhNaVFaYkNtUE9KVk5sTEJvcEVIc0MxdjN6RFJHZDhRd1hPZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-30T13:32:54+00:00", "published_display": "30 Oct 2021 13:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10", "summary": "Roth MKM has reiterated its Buy rating for Entrada Therapeutics (TRDA.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/70998616/roth-mkm-maintains-entrada-therapeutics-trdaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-15T13:11:06", "published_display": "15 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (TRDA) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models to provide tactical trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but strong mid and long-term support signals, offering specific entry", "url": "https://news.stocktradersdaily.com/news_release/1/Why_TRDA_Price_Action_Is_Critical_for_Tactical_Trading_071026094802_1783691282.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T10:09:42", "published_display": "10 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of investors. This investigation follows a significant stock price drop of 57.27% on May 7, 2026, after the company announced \"positive\" Phase 1/2 clin", "url": "https://www.natlawreview.com/press-releases/entrada-therapeutics-inc-trda-investigation-bronstein-gewirtz-grossman-llc-2", "source_name": "The National Law Review", "published_at": "2026-07-03T21:10:57", "published_display": "03 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (TRDA)", "summary": "This article analyzes Entrda Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, with speci", "url": "https://news.stocktradersdaily.com/news_release/10/Understanding_Momentum_Shifts_in_TRDA_062926084002_1782736802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T08:12:15", "published_display": "29 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Entrada Therapeutics, Inc. \u2013 NASDAQ:TRDA", "summary": "This article displays the \"Price to book forward\" metric for Entrada Therapeutics, Inc. (NASDAQ: TRDA). It appears to be a financial data point presented within the TradingView platform, with no additional textual analysis or details provided. The content is minimalist, focusing ", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:39:43", "published_display": "28 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Entrada Therapeutics, Inc. \u2013 NASDAQ:TRDA", "summary": "This article provides a brief financial overview for Entrada Therapeutics, Inc. (NASDAQ: TRDA), focusing on its forward price-to-earnings ratio. The content primarily lists navigation and platform features of TradingView, where this financial data is presumably presented, rather ", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:10:17", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Entrada Therapeutics, Inc. \u2013 NASDAQ:TRDA", "summary": "This page provides financial information for Entrada Therapeutics, Inc. (NASDAQ: TRDA) on TradingView, specifically focusing on its price-to-sales forward ratio. It also lists various features and services offered by TradingView, including market data, analytical tools, community", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:50", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA)", "summary": "This article provides an overview of Entrada Therapeutics, Inc. (NASDAQ: TRDA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and past financial result", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:39:39", "published_display": "26 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRDA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Entrada Therapeutics, Inc. (TRDA) stock, including current analyst price targets, ratings, and financial data. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA, along with frequently asked questi", "url": "https://www.tradingview.com/symbols/NASDAQ-TRDA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-23T21:40:42", "published_display": "23 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "The article provides a financial overview of Entrada Therapeutics Inc (TRDA), detailing its revenue breakdown, profitability margins, and a competitive comparison. TRDA boasts a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in ", "url": "https://intellectia.ai/en/stock/TRDA/financials", "source_name": "Intellectia AI", "published_at": "2026-06-21T03:39:12", "published_display": "21 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Entrada Therapeutics Inc (TRDA), highlighting its current valuation score of 6.99 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.77, which is significantly below its recent high. The artic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T13:40:09", "published_display": "18 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Entrada Therapeutics Inc.'s (TRDA) revenue breakdown. It indicates that relevant data for business segments and profit contribution have not yet been disclosed by the company. However, it does provide a revenue figure for the United State", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:14", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (TRDA) Movement", "summary": "This article analyzes Entrada Therapeutics Inc. (", "url": "https://news.stocktradersdaily.com/news_release/11/Avoiding_Lag:_Real-Time_Signals_in_TRDA_Movement_061826072802_1781782082.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-18T07:28:00", "published_display": "18 Jun 2026 07:28", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50, ranking 107th in its industry, with an average analyst price target of $16.50. Analysts predominantly rate TRDA as a \"Buy,\" forecasting an expected revenue of 411.43K for the next quarter and an EPS of -$1.05", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:16", "published_display": "17 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Entrada Therapeutics Inc (TRDA) currently holds a financial score of 6.01, ranking 301st out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company's latest quarterly revenue decreased by 95.74% year-o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-trda/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T01:09:16", "published_display": "17 Jun 2026 01:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Stockholders Approve Directors and Equity Plans", "summary": "Entrada Therapeutics Inc. stockholders approved key measures at their annual meeting, including the election of two Class II directors, Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D., and the ratification of Ernst & Young LLP as their independent auditor. Shareholders also appro", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TRDA/pressreleases/2430366/entrada-therapeutics-stockholders-approve-directors-and-equity-plans/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T14:39:12", "published_display": "14 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)", "summary": "Oppenheimer has reiterated a Buy rating on Entrada Therapeutics Inc (TRDA) with a price target of $23.00, following an earlier report by Roth MKM which also maintained a Buy rating and a $10.00 price target. The company recently reported a quarterly revenue of $875 thousand and a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TRDA/pressreleases/2303983/oppenheimer-remains-a-buy-on-entrada-therapeutics-inc-trda/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T11:40:19", "published_display": "14 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity", "summary": "Entrada Therapeutics director and 10% owner Kush Parmar was granted 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options will vest on the earlier of the one-year anniversary of June 10, 2026, or the company\u2019s next annual meeting", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-634b6498918f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:49:55", "published_display": "12 Jun 2026 21:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97", "summary": "Entrada Therapeutics (TRDA) director Gina Chapman was granted 19,000 stock options at an exercise price of $5.97 per share. These options will vest on the earlier of one year from June 10, 2026, or the company's next annual meeting, and are set to expire on June 10, 2036. The tra", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-f46b6cda1311.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:39:55", "published_display": "12 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading", "summary": "Entrada Therapeutics director Radhakrishnan Maha was granted 19,000 stock options, allowing him to purchase common stock at an exercise price of $5.97 per share. These options, granted at no cost, will vest on the earlier of June 10, 2027, or the company's next annual meeting, an", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-3ec39f760b08.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:55", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options", "summary": "Entrada Therapeutics director Peter S. Kim received a grant of 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027, or the company's next annual meeting of stockholders. The transaction was ", "url": "https://www.stocktitan.net/sec-filings/TRDA/form-4-entrada-therapeutics-inc-insider-trading-activity-f48bbe69c5f5.html", "source_name": "Stock Titan", "published_at": "2026-06-12T04:10:55", "published_display": "12 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)", "summary": "This article highlights contrasting analyst sentiments for Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) within the healthcare sector. Entrada Therapeutics receives a Strong Buy consensus with significant upside potential, based on a Buy rating from Guggenheim and Roth MKM. In", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE-N/pressreleases/2374960/analysts-have-conflicting-sentiments-on-these-healthcare-companies-entrada-therapeutics-inc-trda-and-pfizer-pfe/", "source_name": "The Globe and Mail", "published_at": "2026-06-09T15:40:40", "published_display": "09 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in TRDA Response", "summary": "This article provides an in-depth analysis of Entrada Therapeutics Inc. (NASDAQ: TRDA) as of June 7, 2026, highlighting weak near-term sentiment but strong mid and long-term signals. It presents AI-generated trading strategies including position, momentum, and risk hedging, along", "url": "https://news.stocktradersdaily.com/news_release/14/Discipline_and_Rules-Based_Execution_in_TRDA_Response_060726055802_1780826282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-07T05:40:09", "published_display": "07 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (NasdaqGM:TRDA) Stock Forecast & Analyst Predictions", "summary": "Entrada Therapeutics (TRDA) is expected to see its earnings decline by 1.6% per annum, while revenue is projected to grow by 44% yearly. Analysts forecast a net loss per share of US$4.09 next year, leading to a recent consensus price target reduction to US$18.75. The company is a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trda/entrada-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-06-05T21:39:48", "published_display": "05 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (TRDA) on behalf of investors. This investigation follows a significant stock price drop after Entrada announced Phase 1/2 clinical study results for a Duchenne treatment, which, d", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-entrada-therapeutics-inc---trda-302789795.html", "source_name": "PR Newswire", "published_at": "2026-06-04T13:39:21", "published_display": "04 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics\u2019 ELEVATE-45-201 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/independent-safety-data-monitoring-committee-110000031.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T11:00:00+00:00", "published_display": "02 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada gets clearance to escalate dose in DMD trial", "summary": "Entrada Therapeutics Inc. (NASDAQ:TRDA) has received clearance from an independent Data Monitoring Committee to escalate the dose in Cohort 2 of its ELEVATE-45-201 study for Duchenne muscular dystrophy (DMD) to 10 mg/kg, up from 5 mg/kg. The decision follows a review of safety an", "url": "https://www.investing.com/news/company-news/entrada-gets-clearance-to-escalate-dose-in-dmd-trial-93CH-4721493", "source_name": "Investing.com", "published_at": "2026-06-02T11:39:15", "published_display": "02 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial", "summary": "Entrada Therapeutics has announced that an independent Data Monitoring Committee has approved an increase in the dose to 10 mg/kg for Cohort 2 in its Phase 1/2 trial for Duchenne muscular dystrophy. This decision follows positive safety and pharmacokinetic reviews of subjects tre", "url": "https://pluang.com/en/news-feed/komite-pengawas-keamanan-rekomendasikan-dosis-tinggi-entrada-therapeutics", "source_name": "Pluang", "published_at": "2026-06-02T11:39:15", "published_display": "02 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare disease trial tests DMD treatment with once-every-six-week dosing", "summary": "Entrada Therapeutics announced that an independent Data Monitoring Committee recommended escalating the dose of ENTR-601-45 to 10 mg/kg for Cohort 2 in its Phase 1/2 ELEVATE-45-201 study for Duchenne muscular dystrophy. All eight participants from Cohort 1, who received 5 mg/kg, ", "url": "https://www.stocktitan.net/news/TRDA/independent-safety-data-monitoring-committee-recommends-initiation-jcyp2i8c61bn.html", "source_name": "Stock Titan", "published_at": "2026-06-02T10:39:15", "published_display": "02 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entrada-therapeutics-announces-inducement-grants-203000634.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:30:00+00:00", "published_display": "01 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPd04wMVAwaUM4QVp6cl95THBzaGxMb01wQzd0ZzNjNE4tMVFzZjVlZDVlN3VuVml6bmNTQnRCdmxfNzhTRzRzVFFvVVoybFlsMldpY0NmSGxuUXlYZ016WGdqdEhOcG1FVGVrMTNKbi02QUtsMG1yT1lfMUNqejUwbGZjbjY0cHZkM3VSeFF6VHdpamJ6dVVRSlRtMFRscm1DVEdpYUw5bnNHUEx6dmJ3SVMzcGlBQndrQnFuSzhEUXU5Vld6M2FoLURrYTVGY0JzNFZrX210Q3MzSV9vN2NJWFlWTjFWZnlocUFKYjdfLXFONHh5UTJn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile", "summary": "", "url": "https://finance.yahoo.com/m/14e3e8c6-ac63-3515-bca1-0399074b5972/entrada-therapeutics-dmd.html", "source_name": "MarketBeat", "published_at": "2026-05-09T06:07:54+00:00", "published_display": "09 May 2026 06:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Downgrades Entrada Therapeutics to Neutral From Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-downgrades-entrada-therapeutics-122234651.html", "source_name": "MT Newswires", "published_at": "2026-05-08T12:22:34+00:00", "published_display": "08 May 2026 12:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada\u2019s stock drops as DMD drug\u2019s efficacy falls short", "summary": "", "url": "https://finance.yahoo.com/m/39e8932f-639c-3a69-8d26-ecf8a3e1e778/entrada%E2%80%99s-stock-drops-as-dmd.html", "source_name": "Clinical Trials Arena", "published_at": "2026-05-08T10:39:36+00:00", "published_display": "08 May 2026 10:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Shares Decline After Duchenne Muscular Dystrophy Drug Reportedly Misses Analyst Expectations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entrada-therapeutics-shares-decline-duchenne-184304757.html", "source_name": "MT Newswires", "published_at": "2026-05-07T18:43:04+00:00", "published_display": "07 May 2026 18:43", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada shares dive as Duchenne results disappoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNc3JWS3JydDgwMFpnUHR0TC13Q3RSVkd4YmJjYXFPdm1YT3RRdlkwMzlENkE0bHROV3piX01qaFl4SHhkOUV2TEswU1NaUlZHT1hLRDJVaExVdVJndF9qc0NxbDNXdjN4dDhudVpPcFlPSjJudGRSV0daX0g1Uk15a1BIR21TazBCdUFNTW1tTFpTRzBZMUlGcA?oc=5", "source_name": "BioPharma Dive", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQY2J6Z1F3UWMzS3dBVTQzOHpYcmtTMjJIZF9XTHlQQUtJeXVUajNVQmhVbnBPNnJOSUpsR0ZPMEhQVUFjTnJnUG5zT0dsTE5jQ1JrVFhWcF9GZVdjUHpPMnBORG5wMFZwRmFXbFQ5eHpBajRHUkE2MVgxNnJFOHdrV0M2N24yMEZ6aUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQOFNodkNpcW5MN1pwRUU5Q1JHNmNmRUc5NWo4d0ZZNzlHRFJPYlF2RzhUQ21aejFDaDB3a005SVg5bDNvbi14bzhSTkpjTWUtOHhZOVduNXpaNzhCVnUxMGRNUGU0Ql9RSmcxMkRDTndsN0tVal9GTk5id211a3FJYXB0SkkwY1oya3luaWR4Ry1ucXFSem9YazkxTnN1MWJReEs3anBaLXR3QQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duchenne trial readout from Entrada arrives Thursday morning", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQNG1YZUROQmpXWWw1ZkdZcjlGOTRreXhmUi1wV1d0c0lNLXh4YkdLZjhRTWJPYUFpV2dqX3FIN0p0M1FQdVpLZjF4TFMxc1Q4WnpaclJJX25PdnRoVmpXWFhVbEl1Z25vbTVVOTE3bDdIVzNoRUZUaHI3bWFqcXFaNl9ySy1lYm1MbG5MN3FkdG53MlhHS3RYMnd5d1hjeFoxbWlOLWppWmdfRUItYUVhQklHMjNXSVBLZFluMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQaUJlNW1wYi1SWWVXZFJaSFBUXzJpRjRMZjZpOGFaV1RKeUdfeFFadHhidkJwV2pHN0VYLW5nbmFGVFFZeUVHTjhfcGZFemVtam9mYUtXRmFTYklnV0ZhYjctdVdFZU1hWlJhQUJIODZlYjBpTEVUaldYay1jVTJRTjBwSVNnc2gzQm1IVjNwSEhwN3ZlTER1YTZ5QXRHWnFZ?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxORVJBZ3NfM29DWmQ5ZnR4LVE0enc3TVZ3ZmhuVGJGU2xsSU9JZzd6UGdmeGRHOVd0T2EwdU0xeDREUDZoOUkyZ0NNSU9VX2J3R3VJQlJkTFh5VHNMSV9GU3J1RUNqdU5wRFRadWFEYlpHU21uTXB6WVRLNU5MVkdYeV9CdVZLbkdzYWZQa3ZkTlpfWHZQTVFhWUtPT0JOMUJ2dEZCbmtWUlBwZVUtLXpjR1luckhuYWFiUVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOdTk3aml5UHJkNG9QOTJPMTNoTEkwTnIxc280U0l4ckwxWHpjR3hISUZYNmpIeWxQUW9tZlFERmJwNFQwbGZCYUYzVnZwVlN2emdqYXdUY3NDMW4wV1lYU3FlSWpKNUJfaWp6WEpwZzFFOFJnQzNmeTJpbWdWX0N2M3V4LXNUaElEZ0g0QW0yZlh3dlFMZjh0a1otMURMUkJudXN6a1dNV3M3TjZMcnc?oc=5", "source_name": "Finviz", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNcjhCdWFQZm9lSDVESDVTdFNaYWJkT3NXZzdlVVJGQWdSOS01T1Y1c2V5WXpaSDlCaXRMTVgtek9aN05MQ2k2ZHNlaGZPZUltWVpmdDlBUk9Lb3NBcnBDSGpneFVralpLZzgwUnF6MDBMTE5GVGE0NjNWb3hTN1ZvUUNRR09wSWE5dGhWa01UN0VYNzF2STlVclVFVDdhMllPMXVPaUhvTnBQSUhxZzlxYkMyMjN4R1ktQnFZVkV2QzQ1eE5zRlpUdGRsNE12U0Z4cHZra1VMNWhhVGFi?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxOQWo1U1M2SC1ucEpVU1NsbG9iQVdmZFFHTXMtOVRZNlNJQW05WHFHQlBrMmx5YVhGbFE3ZEdZRnlHenhTb3RDenM0WTZxRXhSYTNyZVRNbjFJbTM4US1DZzI0dlpwaEFMTldHQW8wdWZKcm5tcFhvMmUzUUFkNERjMUVoYjlxVGRRT0RtXzZWSndQcXBrOGlZUjk5M2gzWTg0al82RzhYWTFva3BJZkwwX3hZTWRSMlRNSDhfRGpvTmZ1Ri05dW1lMkdjRFZzVC0ycHRVQWpaN1FmcEtPVlp2S0tqNHhJdDNQNG9TUEZxT2JjSm1feVVj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-09T07:00:00+00:00", "published_display": "09 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1mRlQ4NGktTk5Cc2Q3U0JHVDZMbFR0eWVyMkpjMnJYV3dpSExNZGJ4eTl1V1l2ajRsbDhsU21QZ01PMFR3cDE0OUMxYS1FMDBXUUx3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:39:44+00:00", "published_display": "25 Apr 2025 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics - TRDA - Stock Price Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE1IaGRxVVNYMHZhbXA3TXJSSE5nNmxabkRyYkNoQjl4WkE3cXoteG14TnRxY1lNZHZXUGdCOWlHWWFRSEExdEY4Nm94dUxFeU0?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-11-01T05:34:44+00:00", "published_display": "01 Nov 2021 05:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entrada Therapeutics (TRDA) Stock Price, News & Analysis $TRDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE43VDJPUWRlc2QzUVYzcGcwX0dkZXdROXluQzFESFk2NXZObjdrSy1ONjQtc3BfZGhNaVFaYkNtUE9KVk5sTEJvcEVIc0MxdjN6RFJHZDhRd1hPZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-30T13:32:54+00:00", "published_display": "30 Oct 2021 13:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 58, "sentiment_summary": {"positive": 12, "negative": 14, "neutral": 32, "score": 50, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 12, "negative_events": 14}, "market_context": {"has_market_context": true, "latest_close": 6.89, "latest_week": "2026-07-17", "one_week_move": -0.4, "four_week_move": -2.8, "twelve_week_move": -45.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.856572, "market_dynamics_buy_signal": false, "relative_strength": -29.942216, "fair_value_gap": -43.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 53.7772, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "Stock Traders Daily", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "The Globe and Mail", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10"}], "updated_at": "2026-07-21T21:13:16.734830+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}